Intraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies

Simple item page
dc.contributor.authorVasiliki Tzelepi
dc.contributor.authorAngeliki Pomoni
dc.contributor.authorIoanna Maria Grypari
dc.contributor.departmentDepartamento de Biologia Celular e Histiologia
dc.contributor.editorUniversidad de Murcia, Departamento de Biologia Celular e Histiologia
dc.date.accessioned2025-11-10T11:25:03Z
dc.date.available2025-11-10T11:25:03Z
dc.date.issued2025
dc.description.abstractIntraductal carcinoma of the prostate (IDC-P) is characterized by neoplastic cell proliferation within pre-existing ducts or acini, exhibiting architectural and cytological atypia exceeding that of high-grade prostatic intraepithelial neoplasia. Its presence in needle biopsies and prostatectomies is associated with adverse clinical and pathological features, including large tumor volume, high grade, advanced stage, early biochemical recurrence, and intrinsic resistance to systemic therapy. Although rare, IDC-P can occasionally occur without concurrent invasive cancer or be associated with low-grade prostate cancer. Molecularly, IDC-P resembles its associated invasive carcinoma, sharing alterations typical of high-grade aggressive tumors. These findings support the hypothesis that IDC-P arises from the retrograde spread of invasive carcinoma, with ducts providing a protective niche against the tumor microenvironment. In contrast, isolated IDC-P and IDC-P associated with low-grade invasive carcinoma may represent precursor lesions. IDC-P must be distinguished from other intraductal lesions, both benign and malignant, particularly in needle biopsies, as its detection impacts therapeutic decisions. While grading does not apply to isolated IDC-P, there is an ongoing debate regarding IDC-P with synchronous invasive cancer. The International Society of Urological Pathology (2019) recommends incorporating IDC-P into Gleason score calculations, whereas the Genitourinary Pathology Society advises against grading it at all. Both approaches have merit, but further validation studies focusing on cases where IDC-P inclusion alters the final grade, though uncommon, are warranted
dc.formatapplication/pdf
dc.identifier.doihttps://doi.org/ 10.14670/HH-18-939
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/171910
dc.languageeng
dc.relationSin financiacion externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject20
dc.subjectIntraductal carcinoma of the prostate
dc.subjectGUPS 2019
dc.subjectISUP 2019
dc.subjectGrading
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleIntraductal carcinoma of the prostate: A comprehensive literature review focused on grading challenges and controversies
dc.typeinfo:eu-repo/semantics/article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Grypari-40-1869-1888-2025.pdf
Size:
12.63 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.40, Nº12, (2025)